Skip to content

GNFT

Genfit SA

NASDAQ · Healthcare · Biotechnology · FR

$8.95
+4.07%
Ask drillr

Year over year

Reported trailing growth

Revenue
-45.0%
EBITDA
EBIT
EPS
Free cash flow
+89.5%
Operating cash flow
+92.4%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-5.8%
EBITDA
-37.9%
EBIT
-53.1%
Net income
-71.8%
EPS
-72.9%
Free cash flow
-47.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025